Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Exclusion Criteria

• •1. Participants who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
• •2. Prior exposure to any immunosuppressive/immunomodulatory biologic other than TNFi for HS.
• •3. Prior exposure to Interleukin 36 receptor (IL-36R) inhibitors including spesolimab.
• •4. Treated with any investigational device or investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives of the drug, whichever is longer.
• •5. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
• •6. Participants with history of allergy/hypersensitivity to the systemically administered trial medication agent or its excipients.
• •7. Participants with a transplanted organ (with exception of a corneal transplant \>12 weeks prior to screening) or who has ever received stem cell therapy (e.g., Remestemcel-L).
• •8. Participants with any documented active or suspected malignancy or history of malignancy within 5 years prior to the screening visit, except appropriately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix.